- Home
- ANVS vs RLMD Comparison
ANVS vs RLMD Comparison
Compare ANVS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- RLMD
- Stock Information
- Founded
- ANVS 2008
- RLMD 2004
- Country
- ANVS United States
- RLMD United States
- Employees
- ANVS N/A
- RLMD N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- RLMD Health Care
- Exchange
- ANVS Nasdaq
- RLMD Nasdaq
- Market Cap
- ANVS 110.4M
- RLMD 110.6M
- IPO Year
- ANVS 2020
- RLMD N/A
- Fundamental
- Price
- ANVS $6.85
- RLMD $3.01
- Analyst Decision
- ANVS Strong Buy
- RLMD Hold
- Analyst Count
- ANVS 6
- RLMD 2
- Target Price
- ANVS $29.67
- RLMD $7.50
- AVG Volume (30 Days)
- ANVS 261.0K
- RLMD 117.3K
- Earning Date
- ANVS 11-08-2024
- RLMD 11-07-2024
- Dividend Yield
- ANVS N/A
- RLMD N/A
- EPS Growth
- ANVS N/A
- RLMD N/A
- EPS
- ANVS N/A
- RLMD N/A
- Revenue
- ANVS N/A
- RLMD N/A
- Revenue This Year
- ANVS N/A
- RLMD N/A
- Revenue Next Year
- ANVS N/A
- RLMD N/A
- P/E Ratio
- ANVS N/A
- RLMD N/A
- Revenue Growth
- ANVS N/A
- RLMD N/A
- 52 Week Low
- ANVS $4.53
- RLMD $1.88
- 52 Week High
- ANVS $22.49
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- ANVS 30.84
- RLMD 31.18
- Support Level
- ANVS $7.30
- RLMD $3.06
- Resistance Level
- ANVS $8.93
- RLMD $3.43
- Average True Range (ATR)
- ANVS 0.56
- RLMD 0.20
- MACD
- ANVS -0.26
- RLMD -0.05
- Stochastic Oscillator
- ANVS 4.89
- RLMD 6.61
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.